ArticleBioMed research international2020
Immune-Related Four-lncRNA Signature for Patients with Cervical Cancer.
Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Effect of immune-related lncRNA BZRAP1-AS1/miR-541-3p and its molecular mechanism in cervical cancer.World journal of surgical oncology · 2026Article
- Article
- Construction of a novel signature based on immune-related lncRNA to identify high and low risk pancreatic adenocarcinoma patients.BMC gastroenterology · 2023Article
- The function of lncRNA EMX2OS/miR-653-5p and its regulatory mechanism in lung adenocarcinoma.Open medicine (Warsaw, Poland) · 2023Article
- The Immune-related ceRNA Network in Prognosis of Cervical Cancer.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Competing Endogenous RNA (ceRNA) Networks and Splicing Switches in Cervical Cancer: HPV Oncogenesis, Clinical Significance and Therapeutic Opportunities.Microorganisms · 2022Review
- Identifying a cervical cancer survival signature based on mRNA expression and genome-wide copy number variations.Experimental biology and medicine (Maywood, N.J.) · 2022Article
- lncRNA BZRAP1-AS1 alleviates rheumatoid arthritis by regulating miR-1286/COL5A2 axis.Immunity, inflammation and disease · 2022Article
- Long non-coding RNAPeerJ · 2022Article
- Exploration of the Immune-Related Long Noncoding RNA Prognostic Signature and Inflammatory Microenvironment for Cervical Cancer.Frontiers in pharmacology · 2022Article
- Construction of a Prognostic Immune-Related LncRNA Risk Model for Gastric Cancer.Journal of oncology · 2022Article
- Integrated Bioinformatics Analysis of Serine Racemase as an Independent Prognostic Biomarker in Endometrial Cancer.Frontiers in genetics · 2022Article
- Signature of seven cuproptosis-related lncRNAs as a novel biomarker to predict prognosis and therapeutic response in cervical cancer.Frontiers in genetics · 2022Article
- Identification and validation of an immune-related lncRNAs signature to predict the overall survival of ovarian cancer.Frontiers in oncology · 2022Article
- Comprehensive analysis of cuproptosis-related lncRNAs model in tumor immune microenvironment and prognostic value of cervical cancer.Frontiers in pharmacology · 2022Article
- LncRNAInternational journal of molecular sciences · 2021Review
- A Prognostic Model Based on the Immune-Related lncRNAs in Colorectal Cancer.Frontiers in genetics · 2021Article
- A novel lncRNA-mRNA-miRNA signature predicts recurrence and disease-free survival in cervical cancer.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021Article
- Identification and Experimental Validation of Immune-Associate lncRNAs for Predicting Prognosis in Cervical Cancer.OncoTargets and therapy · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cervical cancer (CC) is a common gynecological malignancy for which prognostic and therapeutic biomarkers are urgently needed. The signature based on immune-related lncRNAs (IRLs) of CC has never been reported. This study is aimed at establishing an IRL signature for patients with CC. A cohort of 326 CC and 21 normal tissue samples with corresponding clinical information was included in this study. Twenty-eight IRLs were collected according to the Pearson correlation analysis between the immune score and lncRNA expression (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.